Kexing Biopharm Obtained IND Approval for Its Self-developed GB05 from U.S. FDA

Kexing Biopharm Obtained IND Approval for Its Self-developed GB05 from U.S. FDA

SHENZHEN, China, Feb. 14, 2025 /PRNewswire/ -- Kexing Biopharm Co., Ltd. (Stock Code: 688136.SH) recently announced that the Investigational New Drug Application (IND) of GB05, Human Interferon α1b Inhalation Solution, a self-developed product by...

Kexing Biopharm Participates in the 17th Biotech Showcase, with Multiple Innovation Pipelines Gaining Attention

Kexing Biopharm Participates in the 17th Biotech Showcase, with Multiple Innovation Pipelines Gaining Attention

SHENZHEN, China, Jan. 24, 2025 /PRNewswire/ -- From January 13 to 16, Dr. Huiming Li, Deputy General Manager of Kexing Biopharm New Drug Research Center, attended the 17th Biotech Showcase Conference in San Francisco and the Global Biopharma...

menu
menu